Listeriolysin O expressed in a bacterial vaccine suppresses CD4 +CD25high regulatory T cell function in vivo

Journal of Immunology

Volumn 179, Issue 3, 2007, Pages 1532-1541

  Nitcheu Tefit, Josianne ^a   Dai, Ming Shen ^a,d   Critchley Thorne, Rebecca J ^a,g   Ramirez Jimenez, Francisco ^b   Xu, Man ^a,c   Conchon, Sophie ^e,f   Ferry, Nicolas ^e,f   Stauss, Hans J ^b   Vassaux, Georges ^a,e,f,h  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e UNIVERSITÉ DE NANTES   (France)

^f HÔTEL DIEU   (France)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; CANCER ANTIBODY; ESCHERICHIA COLI VACCINE; GAMMA INTERFERON; LISTERIOLYSIN O; OVALBUMIN; TRANSCRIPTION FACTOR FOXP3; BACTERIAL TOXIN; EGG PROTEIN; HEAT SHOCK PROTEIN; HEMOLYSIN; HLYA PROTEIN, LISTERIA MONOCYTOGENES; INACTIVATED VACCINE; OVA 8; OVA-8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LUNG METASTASIS; LUNG TUMOR; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR CELL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METASTASIS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BACTERIAL TOXINS; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL PROLIFERATION; EGG PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED; VACCINES, INACTIVATED;

EID: 34548642945     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.3.1532     Document Type: Article

References (46)

1. Beyer, M., and J. L. Schultze. 2006. Regulatory T cells in cancer. Blood 108: 804-811.
2. Pan, Z. K., G. Ikonomidis, A. Lazenby, D. Pardoll, and Y. Paterson. 1995. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1: 471-477.
3. Darji, A., C. A. Guzman, B. Gerstel, P. Wachholz, K. N. Timmis, J. Wehland, T. Chakraborty, and S. Weiss. 1997. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91: 765-775.
4. Pan, Z. K., L. M. Weiskirch, and Y. Paterson. 1999. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 59: 5264-5269.
5. Gunn, G. R., A. Zubair, C. Peters, Z. K. Pan, T. C. Wu, and Y. Paterson. 2001. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167: 6471-6479.
6. Radford, K. J., D. E. Higgins, S. Pasquini, E. J. Cheadle, L. Carta, A. M. Jackson, N. R. Lemoine, and G. Vassaux. 2002. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther. 9: 1455-1463.
7. Brockstedt, D. G., K. S. Bahjat, M. A. Giedlin, W. Liu, M. Leong, W. Luckett, Y. Gao, P. Schnupf, D. Kapadia, G. Castro, et al. 2005. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat. Med. 11: 853-860.
8. Brockstedt, D. G., M. A. Giedlin, M. L. Leong, K. S. Bahjat, Y. Gao, W. Luckett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky, Jr. 2004. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101: 13832-13837.
9. Singh, R., M. E. Dominiecki, E. M. Jaffee, and Y. Paterson. 2005. Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 175: 3663-3673.
10. Loessner, H., and S. Weiss. 2004. Bacteria-mediated DNA transfer in gene therapy and vaccination. Expert Opin. Biol. Ther. 4: 157-168.
11. Paterson, Y., and P. C. Maciag. 2005. Listeria-based vaccines for cancer treatment. Curr. Opin. Mol. Ther. 7: 454-460.
12. Vassaux, G., J. Nitcheu, S. Jezzard, and N. R. Lemoine. 2006. Bacterial gene therapy strategies. J. Pathol. 208: 290-298.
13. Critchley-Thorne, R. J., A. J. Stagg, and G. Vassaux. 2006. Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination. Mol. Ther. 14: 183-191.
14. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
15. Poltorak, A., P. Ricciardi-Castagnoli, S. Citterio, and B. Beutler. 2000. Physical contact between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. Proc. Natl. Acad. Sci. USA 97: 2163-2167.
16. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
17. Gewirtz, A. T., T. A. Navas, S. Lyons, P. J. Godowski, and J. L. Madara. 2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 167: 1882-1885.
18. Beauregard, K. E., K. D. Lee, R. J. Collier, and J. A. Swanson. 1997. pH-dependent perforation of macrophage phagosomes by listeriolysin O from Listeria monocytogenes. J. Exp. Med. 186: 1159-1163.
19. Provoda, C. J., and K. D. Lee. 2000. Bacterial pore-forming hemolysins and their use in the cytosolic delivery of macromolecules. Adv. Drug Deliv. Rev. 41: 209-221.
20. Higgins, D. E., N. Shastri, and D. A. Portnoy. 1999. Delivery of protein to the cytosol of macrophages using Escherichia coli K-12. Mol. Microbiol. 31: 1631-1641.
21. + T cells. Int. J. Cancer 105: 811-819.
22. + T cells following uptake by human APC. J. Immunol. 172: 1595-1601.
23. Dahl, A. M., P. C. Beverley, and H. J. Stauss. 1996. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157: 239-246.
24. Carrero, J. A., B. Calderon, and E. R. Unanue. 2004. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 200: 535-540.
25. Carrero, J. A., B. Calderon, and E. R. Unanue. 2006. Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes. J. Exp. Med. 203: 933-940.
26. Bellone, M., D. Cantarella, P. Castiglioni, M. C. Crosti, A. Ronchetti, M. Moro, M. P. Garancini, G. Casorati, and P. Dellabona. 2000. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165: 2651-2656.
27. Blander, J. M., D. B. Sant'Angelo, D. Metz, S. W. Kim, R. A. Flavell, K. Bottomly, and C. A. Janeway, Jr. 2003. A pool of central memory-like CD4 T cells contains effector memory precursors. J. Immunol. 170: 2940-2948.
28. + T cells. J. Immunol. 173: 883-891.
29. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
30. + regulatory T cells that secrete TGFβ and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 27: 339-346.
31. North, R. J. 1984. γ-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol. Immunother. 16: 175-181.
32. North, R. J., and M. Awwad. 1987. T cell suppression as an obstacle to immunologically-mediated tumor regression: elimination of suppression results in regression. Prog. Clin. Biol. Res. 244: 345-358.
33. + T cell-mediated immunity. J. Exp. Med. 168: 2193-2206.
34. + T cells to cause regression of an advanced lymphoma. Immunology 71: 90-95.
35. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182: 18-32.
36. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832.
37. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
38. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
39. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
40. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. 26: 85-93.
41. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173: 1444-1453.
42. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
43. Ichihara, F., K. Kono, A. Takahashi, H. Kawaida, H. Sugai, and H. Fujii. 2003. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9: 4404-4408.
44. Dannull, J., Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, and J. Vieweg. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115: 3623-3633.
45. Gillmore, R., S. A. Xue, A. Holler, J. Kaeda, D. Hadjiminas, V. Healy, R. Dina, S. C. Parry, I. Bellantuono, Y. Ghani, et al. 2006. Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin. Cancer Res. 12: 34-42.
46. Xue, S., L. Gao, R. Gillmore, G. Bendle, A. Holler, A. M. Downs, A. Tsallios, F. Ramirez, Y. Ghani, D. Hart, et al. 2004. WT1-targeted immunotherapy of leukaemia. Blood Cells Mol. Dis. 33: 288-290.